Endothelial progenitor cells as putative targets for angiostatin

Area of Science:

• Oncology
• Cell Biology
• Vascular Biology

Background:

• Angiostatin, derived from plasminogen, exhibits antitumor and antiangiogenic effects in vivo.
• In vitro studies show variable effects of angiostatin on mature endothelial cells, with less potency than observed in vivo.
• A discrepancy exists between angiostatin's in vitro and in vivo efficacy, suggesting a different primary target.

Purpose of the Study:

• To investigate the differential sensitivity of endothelial progenitor cells (EPCs) and mature endothelial cells to angiostatin.
• To explore the role of EPCs as the primary in vivo target of angiostatin's antiangiogenic activity.

Main Methods:

• Isolation of endothelial progenitor cells (EPCs) from human subjects.
• Assessment of angiostatin's effect on the proliferation and survival of isolated EPCs and mature endothelial cells in vitro.

Main Results:

• Endothelial progenitor cells (EPCs) demonstrated exquisite sensitivity to angiostatin.
• Mature endothelial cells showed significantly less sensitivity to angiostatin compared to EPCs.
• Angiostatin's potent effects were primarily observed on EPCs, not mature endothelial cells.

Conclusions:

• Angiostatin exerts its potent antiangiogenic and antitumor effects by inhibiting endothelial progenitor cells (EPCs).
• The biological activity of angiostatin is likely mediated through its action on EPCs, rather than mature endothelial cells.
• This highlights EPCs as a key target for angiostatin-based therapies in cancer treatment.